Streetbeat News

VANI

Vivani Medical, Inc.

https://www.vivani.com

Industry

Medical - Devices

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Vivani Medical (NASDAQ:VANI) reported a Q2 2024 adjusted EPS of $(0.10), beating the analyst consensus estimate of $(0.12) by 16.67%.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:23 pm

Insiders are buying shares of Pineapple Financial Inc. (NYSE:PAPL) and Vivos Inc. (OTC:RDGL), indicating confidence in these companies despite recent challenges. Pineapple Financial's CSO bought 2,000 shares after a wider-than-expected quarterly loss, while Vivos' CEO acquired 50,000 shares following an FDA application for human clinical trials.

Portfolio Pulse from Avi Kapoor

August 05, 2024 | 1:13 pm

Insiders are buying shares of Vivani Medical, RENN Fund, and Cyanotech, indicating their confidence in these companies. Notable transactions include purchases by executives and directors, with Vivani Medical planning a clinical study in 2024.

Portfolio Pulse from Avi Kapoor

August 02, 2024 | 11:41 am

Signet Jewelers Limited (NYSE:SIG) shares fell over 12% due to mixed first-quarter earnings, including a significant drop in same-store sales. The company reported a 9.5% year-on-year sales decline, missing analyst estimates, but beat EPS expectations. Other stocks mentioned include BioRestorative Therapies, Zapp Electric Vehicles, Sharps Technology, and Broadcom, among others, with various gains and losses based on recent announcements and earnings reports.

Portfolio Pulse from Avi Kapoor

June 13, 2024 | 6:07 pm

Vivani Medical, Inc. (NASDAQ:VANI) shares are trading higher after the FDA cleared the Investigational New Drug application and lifted the clinical hold on NPM-119, allowing the initiation of the LIBERATE-1 Phase 1 clinical trial. This trial will assess the safety, tolerability, and pharmacokinetics of NPM-119, a six-month GLP-1 implant for type 2 diabetes. The stock saw heavy trading volume, with over 11.7 million shares traded compared to the 100-day average of less than 174,000 shares.

Portfolio Pulse from Erica Kollmann

June 13, 2024 | 3:18 pm

Vivani Medical shares are trading higher after the company announced the FDA cleared the Investigational New Drug Application and lifted the clinical hold on NPM-119.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 12:08 pm

The article highlights the pre-market movements of 12 health care stocks on Thursday. Significant gainers include Longeveron (LGVN), JanOne (JAN), Bionomics (BNOX), BioRestorative Therapies (BRTX), Holdco Nuvo Group DG (NUVO), and Vivani Medical (VANI). Notable losers are Assure Holdings (IONM), Cara Therapeutics (CARA), Apyx Medical (APYX), Petros Pharma (PTPI), Catheter Precision (VTAK), and Connect Biopharma Holdings (CNTB).

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 12:07 pm

Vivani Medical, Inc. (NASDAQ:VANI) announced that the FDA has cleared its Investigational New Drug Application for NPM-119, allowing the commencement of the LIBERATE-1 Phase 1 trial. This trial will evaluate the safety, tolerability, and pharmacokinetics of Vivani’s six-month GLP-1 implant for type 2 diabetes. The study is set to start in the second half of the year. Vivani is also developing other drug implants targeting chronic weight management.

Portfolio Pulse from Akanksha Bakshi

June 13, 2024 | 11:01 am

Vivani Medical announced that their upcoming study will be the first clinical application of NanoPortal, their proprietary implant platform technology.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:00 am

Vivani Medical is studying NPM-119 to address medication non-adherence and improve tolerability issues associated with oral and injectable type 2 diabetes medications.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.